Professor Rakesh Heer

Professor Rakesh Heer is a highly esteemed consultant urologist based in London. He has extensive experience in general and specialist urology. He is renowned for his expertise in urinary problems, prostate concerns, blood in the urine, men’s sexual health and penile and scrotal conditions. His specialist interests include all aspects of prostate cancer and bladder cancer diagnosis and management.

Professor Heer qualified in medicine from the University of Nottingham in 1997, before pursuing further training in Newcastle. In 2006, he completed a PhD at Newcastle University, receiving the European Urology Association’s prize in 2008 for best urological paper published in international literature. In 2010, he was also awarded a highly-sought-after Hunterian Professorship from the Royal College of Surgeons of England and a highly prestigious clinician scientist fellowship from Cancer Research UK for his cutting-edge research. In this time, his work focused on ground-breaking studies into prostate cancer. In 2011, he was appointed as a consultant urologist in Newcastle, where he ultimately became professor. He recently moved to a new professorial position at Imperial College London as Chair of Urology. In 2021, he received a National Clinical Excellence award from the Department of Health in recognition of his dedication to patient care, expertise and leadership in the field of urology. Professor Heer sees private patients at multiple sites across Central London, including The Shard, Lister Hospital Chelsea, Basinghall Clinic, The Cromwell, Old Broad Street and Canary Wharf.

Additional to his clinical responsibilities, Professor Heer is a highly respected educator in the field of urology. He was co-director of the annual UK cadaveric robotic course for several years, training many consultants from the UK and worldwide. He also previously held senior roles as Newcastle University's Associate Dean and Director of MD studies.

Professor Heer is also a globally renowned leader in urology research, helping shape current, patient-centric, and high-quality clinical practice. He is chief investigator in a number of important cutting edge trials, including those conducted by the National Institute for Health and Care Research (NIHR) in prostate cancer, bladder cancer and kidney cancer. He holds a number of important national leadership roles, including chairman for clinical guidelines, writing for the National Institute for Health and Care Excellence (NICE), as well as chairman for the National Cancer Research Institute (NCRI) localised prostate cancer subgroup. He remains actively involved in research and has published numerous academic papers in esteemed peer-reviewed journals.